Current Clinical Trials
We're focused on developing treatments for rare CNS conditions that deserve more attention and support.
Our late-stage clinical studies are designed with one guiding principle: What would make a difference in someone’s everyday life?
These studies represent partnerships with people who share our belief that meaningful progress is possible. We currently have a series of late stage studies in the Developmental and Epileptic Encephalopathy (DEE), Focal Onset Seizures, and Essential Tremor.
Clinical Studies for Developmental and Epileptic Encephalopathy (DEE).
To learn more about the EMBOLD study for children diagnosed with SCN2A and SCN8A DEEs, please visit resiliencestudies.com/embold
The EMBRAVE study is investigating a new potential treatment for children with early-onset SCN2A DEE.
To learn more about the EMBRAVE study for children diagnosed with early-onset SCN2A DEEs, please visit resiliencestudies.com/embrave
The EMERALD study is evaluating a potential new treatment to reduce seizures caused by Development and Epileptic Encephalopathies (DEEs). For more information, visit resiliencestudies.com/emerald
Clinical Studies for Essential Tremor and Focal Onset Seizures
Essential3 study is an at-home research study evaluating an investigational drug, to see if it may improve your ability to complete everyday tasks, such as eating, drinking and dressing. The Essential3 study has been designed so that you may participate from the comfort of your own home. For more information, visit www.essential3study.com
The POWER1 study is a research study evaluating a new investigational drug as a potential treatment for focal onset seizures in adults. For more information, visit www.power1study.com